Available strengths

Condition-specific dosing for XARELTO®

Available Strengths

2.5mg strength of dosing

10mg strength of dosing

15mg strength of dosing

20mg strength of dosing

Tablets not shown to actual size.

Download

Dosing Guide

The complete guide to dosing for XARELTO®

Download

Prescribing Information

Full Prescribing Information for XARELTO®

NVAF

NVAF: Reducing stroke risk

20mg strength of dosing

20 mg once daily with the evening meal in patients with a CrCl >50 mL/min

15mg strength of dosing

15 mg moderate-to-severe renal impairment dose

Once daily with the evening meal in patients with a CrCl 50 mL/min

Renal Dosing Considerations

Periodically assess renal function as clinically indicated (ie, more frequently in situations in which renal function may decline) and adjust therapy accordingly. Consider dose adjustment or discontinuation of XARELTO® in patients who develop acute renal failure while on XARELTO®

See section 8.6 of the Prescribing Information for additional information

CAD/PAD

CAD: Reducing the risk of major CV events

PAD: Reducing the risk of major thrombotic vascular events, including patients after LER due to symptomatic PAD

2.5mg strength of dosing

2.5 mg twice daily, with or without food, in combination with aspirin (75 mg-100 mg) once daily

No dose adjustment needed based on CrCl

When starting therapy after a successful LER procedure, initiate once hemostasis has been established

DVT/PE:

DVT treatment

15mg strength of dosing

For the first 21 days, 15 mg twice daily with food, at the same time each day in patients with a CrCl 15 mL/min

20mg strength of dosing

Starting at day 22, change to 20 mg once daily with food, at the same time each day, for remaining treatment in patients with a CrCl 15 mL/min

Avoid use in patients with CrCl <15 mL/min

PE treatment

15mg strength of dosing

For the first 21 days, 15 mg twice daily with food, at the same time each day in patients with a CrCl 15 mL/min

20mg strength of dosing

Starting at day 22, change to 20 mg once daily with food, at the same time each day, for remaining treatment in patients with a CrCl 15 mL/min

Avoid use in patients with CrCl <15 mL/min

DVT/PE:

Reduction in the risk of recurrence

10mg strength of dosing

10 mg once daily with or without food after 6 months of standard anticoagulant treatment in patients with a CrCl 15 mL/min

Avoid use in patients with CrCl <15 mL/min

DVT PROPHYLAXIS:

After hip replacement surgery

10mg strength of dosing

10 mg once daily for 35 days, 6 to 10 hours after surgery once hemostasis has been established, with or without food, in patients with a CrCl 15 mL/min

Avoid use in patients with CrCl <15 mL/min

DVT PROPHYLAXIS:

After knee replacement surgery

10mg strength of dosing

10 mg daily for 12 days, 6 to 10 hours after surgery once hemostasis has been established, with or without food, in patients with a CrCl 15 mL/min

Avoid use in patients with CrCl <15 mL/min

VTE PROPHYLAXIS:

Acutely ill medical patients

10mg strength of dosing

10 mg once daily, in hospital and after hospital discharge, for a total recommended duration of 31 to 39 days, with or without food, in patients with a CrCl 15 mL/min

Avoid use in patients with CrCl <15 mL/min

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

CAD = coronary artery disease; CrCl = creatinine clearance; CV = cardiovascular; DVT = deep vein thrombosis; LER = lower extremity revascularization; NVAF = nonvalvular atrial fibrillation; PAD = pulmonary artery disease; PE = pulmonary embolism; VTE = venous thromboembolism.